Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903)
CONCLUSION: The 26.7% objective response rate with anastrozole is lower than reported in retrospective series, but the CBR was high and durable. The results underscore the importance of prospective trials in rare cancers.PMID:33608144 | DOI:10.1016/j.ygyno.2021.02.016 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 20, 2021 Category: Cancer & Oncology Authors: M Friedlander C Benson R L O'Connell N Reed A Clamp R Lord D Millan S Nottley F Amant C Steer A Anand L Mileshkin P Beale S Banerjee N Bradshaw C Kelly K Carty L Divers L Alexander R Edmondson Source Type: research
PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial
CONCLUSION: PAM-50 can be used as a prognostic tool for local recurrence risk in postmenopausal women with hormone receptor-positive breast cancer treated with endocrine therapy. The test was not predictive for the benefit of radiotherapy.PMID:33608712 | DOI:10.1093/bjs/znaa089 (Source: The British Journal of Surgery)
Source: The British Journal of Surgery - February 20, 2021 Category: Surgery Authors: F Fitzal M Filipits C Fesl M Rudas R Greil M Balic F Moinfar W Herz P Dubsky R Bartsch S Ferree C Schaper M Gnant Source Type: research
PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial.
CONCLUSION: PAM-50 can be used as a prognostic tool for local recurrence risk in postmenopausal women with hormone receptor-positive breast cancer treated with endocrine therapy. The test was not predictive for the benefit of radiotherapy.
PMID: 33608712 [PubMed - as supplied by publisher] (Source: The British Journal of Surgery)
Source: The British Journal of Surgery - February 20, 2021 Category: Surgery Authors: Fitzal F, Filipits M, Fesl C, Rudas M, Greil R, Balic M, Moinfar F, Herz W, Dubsky P, Bartsch R, Ferree S, Schaper C, Gnant M Tags: Br J Surg Source Type: research
Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903).
CONCLUSION: The 26.7% objective response rate with anastrozole is lower than reported in retrospective series, but the CBR was high and durable. The results underscore the importance of prospective trials in rare cancers.
PMID: 33608144 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 16, 2021 Category: Cancer & Oncology Authors: Friedlander M, Benson C, O'Connell RL, Reed N, Clamp A, Lord R, Millan D, Nottley S, Amant F, Steer C, Anand A, Mileshkin L, Beale P, Banerjee S, Bradshaw N, Kelly C, Carty K, Divers L, Alexander L, Edmondson R Tags: Gynecol Oncol Source Type: research
Palliative treatment of endometrial cancer: what is the role of anastrozole in elderly women?
Type I endometrial cancer is the most common gynaecological tumour in developed countries and its incidence is increasing also because of population aging. The aim of this work is to test the feasibility and s... (Source: BMC Palliative Care)
Source: BMC Palliative Care - February 5, 2021 Category: Palliative Care Authors: Barbara Gardella, Mattia Dominoni, Stefano Bogliolo, Chiara Cassani, Giulia Vittoria Carletti, Annalisa De Silvestri and Arsenio Spinillo Tags: Research article Source Type: research
Box-Behnken Design Optimized TPGS Coated Bovine Serum Albumin Nanoparticles Loaded with Anastrozole.
CONCLUSION: The BBD optimized TPGS-ANZ-BSA nanoparticles showed enhanced physiochemical properties for ANZ and potential candidate for anticancer agent drugs delivery.
PMID: 33530907 [PubMed - as supplied by publisher] (Source: Current Drug Delivery)
Source: Current Drug Delivery - February 1, 2021 Category: Drugs & Pharmacology Authors: Kumar A, Singh A, Flora SJS, Shukla R Tags: Curr Drug Deliv Source Type: research
Long-term effect of aromatase inhibition in aromatase excess syndrome.
CONCLUSIONS: Spontaneous growth in AEXS varied, even in the same family. Our data suggest that early started, long-term inhibition by anastrozole promotes adult height in boys with AEXS.
PMID: 33513243 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - January 29, 2021 Category: Endocrinology Authors: Binder G, Nakamura A, Schweizer R, Ogata T, Fukami M, Nagasaki K Tags: J Clin Endocrinol Metab Source Type: research
Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial
British Journal of Cancer, Published online: 22 January 2021; doi:10.1038/s41416-020-01228-2Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial (Source: British Journal of Cancer)
Source: British Journal of Cancer - January 22, 2021 Category: Cancer & Oncology Authors: Ivana Sestak Glen Blake Raj Patel Jack Cuzick Anthony Howell Robert Coleman Richard Eastell Source Type: research
A Prospective Study on Metronomic Scheduling of Non-chemotherapeutic Drugs in Advanced Epithelial Ovarian Cancers
The objectives of this study are to assess the role of non-chemotherapeutic combination of drugs as maintenance therapy, after standard treatment, for advanced epithelial ovarian cancers (EOC) and to determine the recurrence-free survival (RFS) and cancer-specific survival (CSS). One hundred women with advanced high-grade EOC who had completed standard treatment by primary/interval debulking surgery followed by adjuvant chemotherapy were randomised to either receive (study group) or not to receive (control group) the non-chemotherapeutic maintenance therapy (oral metformin, anastrozole, aspirin, atorvastatin, vitamin D, in...
Source: Indian Journal of Surgical Oncology - January 7, 2021 Category: Cancer & Oncology Source Type: research
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials
ConclusionsWhile higher rates of adverse events were reported in older patients, they were manageable with dose adjustments and concomitant medication. Importantly, a consistent efficacy benefit was observed across all age groups.Clinical trial registrationClinicalTrials.gov: NCT02107703 (first posted April 8, 2014) and NCT02246621 (first posted September 23, 2014). (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 3, 2021 Category: Cancer & Oncology Source Type: research
Cancers, Vol. 12, Pages 3697: Long-Term Evaluation of Women Referred to a Breast Cancer Family History Clinic (Manchester UK 1987 –2020)
Cancers, Vol. 12, Pages 3697: Long-Term Evaluation of Women Referred to a Breast Cancer Family History Clinic (Manchester UK 1987–2020)
Cancers doi: 10.3390/cancers12123697
Authors:
Anthony Howell
Ashu Gandhi
Sacha Howell
Mary Wilson
Anthony Maxwell
Susan Astley
Michelle Harvie
Mary Pegington
Lester Barr
Andrew Baildam
Elaine Harkness
Penelope Hopwood
Julie Wisely
Andrea Wilding
Rosemary Greenhalgh
Jenny Affen
Andrew Maurice
Sally Cole
Julia Wiseman
Fiona Lalloo
David P. French
D. Gareth Evans
Clinics for women concerned about their family history of breast cancer are wid...
Source: Cancers - December 9, 2020 Category: Cancer & Oncology Authors: Anthony Howell Ashu Gandhi Sacha Howell Mary Wilson Anthony Maxwell Susan Astley Michelle Harvie Mary Pegington Lester Barr Andrew Baildam Elaine Harkness Penelope Hopwood Julie Wisely Andrea Wilding Rosemary Greenhalgh Jenny Affen Andrew Maurice Sally Co Tags: Article Source Type: research
Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review
AbstractEndocrine therapy (ET) is integral to the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2 −) metastatic breast cancer (MBC). Aromatase inhibitors (AIs; e.g., anastrozole, letrozole, exemestane), selective estrogen receptor modulators (e.g., tamoxifen), and the selective estrogen receptor degrader, fulvestrant, inhibit tumor cell proliferation by targeting ER signaling. However, the eff icacy of ET could be limited by intrinsic and acquired resistance mechanisms, which has prompted the development of targeted agents and combination strategies. In recent years, ...
Source: Advances in Therapy - November 15, 2020 Category: Drugs & Pharmacology Source Type: research
Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer
Conclusions
We identified a SNP-based model that had excellent performance characteristics for predicting the phenotype of elevated E1 and E2 in women treated with anastrozole. This model was not validated in an independent dataset but that dataset was clinically and genomically substantially different. The model will need validation in a prospective study. (Source: Pharmacogenetics and Genomics)
Source: Pharmacogenetics and Genomics - November 7, 2020 Category: Genetics & Stem Cells Tags: Original Articles Source Type: research
Anastrozole-Associated Lichenoid Eruption
No abstract available (Source: American Journal of Therapeutics)
Source: American Journal of Therapeutics - November 1, 2020 Category: Drugs & Pharmacology Tags: Letters to the Editor Source Type: research
Perioperative Use of Antiestrogen Therapies in Breast Reconstruction: A Systematic Review and Treatment Recommendations
Background
Patients with hormone receptor-positive breast tumors receive hormonal therapy with either selective estrogen receptor modulators (SERMs) (eg, tamoxifen) or aromatase inhibitors (AIs) (eg, anastrozole) for 5 to 10 years. Patients are using these therapies frequently during breast reconstruction. Literature investigating the effects of hormonal modulators on breast reconstruction outcomes demonstrates conflicting results. We sought to perform a systematic evaluation to assess the effects of hormonal therapy on breast reconstruction outcomes and to guide perioperative management of antiestrogen therapies.
Metho...
Source: Annals of Plastic Surgery - September 15, 2020 Category: Cosmetic Surgery Tags: Review Paper Source Type: research
